<DOC>
	<DOCNO>NCT00002194</DOCNO>
	<brief_summary>To evaluate potential pharmacokinetic interaction nevirapine clarithromycin , determine effect nevirapine cytochrome P450 3A4 ( CYP3A4 ) activity vivo .</brief_summary>
	<brief_title>An Open-Label Study HIV+ Patients Determine Effects Nevirapine ( Viramune ) Pharmacokinetics Clarithromycin Activity Cytochrome 3A4 .</brief_title>
	<detailed_description>The study conduct two separate group . Patients Group I receive clarithromycin orally 32 day nevirapine orally 28 day . Patients Group II receive erythromycin intravenously day 0 , 14 , 28 , 43 nevirapine orally 28 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral drug ( i.e. , zidovudine , zalcitabine , stavudine , lamivudine , didanosine , indinavir , saquinavir ) provide change dose medication &gt; 25 % within 4 week study entry . Patients must : HIV positive status . CD4 count &gt; = 100 cells/mm3 . Prior Medication : Allowed : Patients may clarithromycin study entry . Exclusion Criteria Coexisting Condition : Patients follow condition exclude : Malabsorption , severe chronic diarrhea , inability maintain adequate oral intake . Concurrent Medication : Excluded : Macrolide antibiotic ( erythromycin , azithromycin , dirithromycin ) , azole fungals ( ketoconazole , fluconazole , itraconazole ) , rifampin , rifabutin , phenytoin , terfenadine , astemizole , cisapride , triazolam , midazolam , nonnucleoside reverse transcriptase inhibitor , antibiotic contain clavulanic acid , Augmentin . Patients follow prior condition exclude : History drug allergy know drug hypersensitivity . History clinically important disease include hepatic , renal , cardiovascular , gastrointestinal disease . Prior Medication : Excluded : Investigational drug antineoplastic agent within 12 week study entry . Participation clinical trial use ERMBY within one year study entry . Systemic treatment drug know potent hepatic enzyme inducer inhibitor ( e.g. , oral macrolide antibiotic , azole antifungal , cimetidine , rifampin , rifabutin , carbamazepine ) within 28 day study entry . Use protease inhibitor ; ritonavir , nelfinavir , indinavir , nonnucleoside reverse transcriptase inhibitor compound e.g. , delavirdine ) within 4 week study entry . Prior Treatment : Excluded : Radiotherapy within 12 week study entry . Risk Behavior : Excluded : Current history ( within last year ) IVDA , ETOH , substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>Antibiotics , Macrolide</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Cytochrome P-450</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>